Amyris Collaborates with Infectious Disease Research Institute to Advance a Novel Ribonucleic Acid Vaccine Platform with Covid-19 Vaccine

Amyris | October 23, 2020

Amyris Collaborates with Infectious Disease Research Institute to Advance a Novel Ribonucleic Acid Vaccine Platform with Covid-19 Vaccine
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced the signing of a Collaboration Agreement and License Agreement with the Infectious Disease Research Institute (IDRI) to advance a novel ribonucleic acid (RNA) vaccine platform, including accelerating the development of a COVID-19 vaccine. The collaboration will combine IDRI's RNA vaccine platform, including IDRI's proprietary nanostructured lipid carrier (NLC) platform, with Amyris's semi-synthetic squalene. This has the potential to offer differentiated advantages over other RNA vaccines, including superior scalability, efficacy, and sustainability. Amyris will co-own intellectual property developed to create the COVID-19 vaccine, any rights in any combination of IDRI materials and Amyris squalene, the pre-clinical and Phase I clinical trial data, and the Clinical Study Report.

Spotlight

The objective of this chapter is to give an overview and analysis of the current trends and developments in biotechnology in aquaculture research and management. The technological developments along with structural changes in the aquaculture sector may affect access and intellectual property rights (IPR) regimes.

Spotlight

The objective of this chapter is to give an overview and analysis of the current trends and developments in biotechnology in aquaculture research and management. The technological developments along with structural changes in the aquaculture sector may affect access and intellectual property rights (IPR) regimes.

Related News

AI

Charles River and Valence Discovery Declare Strategic Partnership to Provide AI-Enabled Drug Design Capabilities to Clients

Valence Discovery, Charles River | April 08, 2021

Charles River Laboratories International, Inc. and Valence Discovery today reported the arrangement of an essential association to give customers admittance to Valence's computerized reasoning stage for sub-atomic property expectation, generative science, and multiparameter improvement. Expanding on research done by Valence's establishing group at Mila, the world's biggest profound learning research organization, the Valence stage empowers the plan of little atom drug up-and-comers in novel districts of compound space, trailed by quick streamlining against project-explicit strength, selectivity, security, and pharmacology rules. Valence has spearheaded the utilization of few-shot learning in drug configuration, permitting the organization to open forecast errands for which just modest quantities of preparing information are accessible, defeating a basic constraint of existing AI advances in drug revelation. Banding together to Accelerate Discoveries By consolidating top tier AI advances with Charles River's start to finish abilities, the coalition can possibly essentially speed up revelation endeavors from hit plan through lead improvement. Through the cooperation, Charles River customers will have the alternative to get to Valence's foundation to help their medication revelation endeavors. When exploiting this alternative, customers can expect expanded variety in substance matter being examined, in mix with more fast improvement against complex, project-explicit plan measures, at last diminishing courses of events and improving achievement rates for drug revelation projects. Affirmed Quotes "This coordinated effort reflects Charles River's continuous obligation to improving our arrangement of creative innovation arrangements. We anticipate utilizing Valence's exceptional stage to improve results for our customers." – Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services, Charles River "The Valence stage offers a stage change improvement over existing again plan advancements. We've been reliably intrigued by Valence Discovery's capacity to create top notch synthetic matter that is promptly synthesizable, in novel areas of compound space, from datasets not in any case open to AI strategies." – Grant Wishart, PhD, Director of Computer Aided Drug Design, Charles River "We are excited to collaborate with Charles River, a worldwide pioneer trusted by numerous individuals of the world's top drug and biotech organizations. This cooperation is a significant advance in facilitating our central goal of engaging each medication disclosure researcher with the most recent developments in AI-empowered medication plan."– Daniel Cohen, CEO of Valence Discovery About Valence's AI-Enabled Drug Design Platform The Valence stage develops the scholarly community driving exploration done by the organization's establishing group at Mila, the world's biggest profound learning research foundation. Specifically, Valence has spearheaded the use of not many shot learning in drug configuration, permitting the organization to open forecast assignments for which just limited quantities of preparing information are accessible, including novel targets and complex ADME models, while additionally guaranteeing that AI-produced particles are of high therapeutic science quality and promptly synthesizable. Also, Valence utilizes dynamic learning and iterative improvement procedures to guarantee that lone the most data rich mixtures are chosen for amalgamation, empowering the plan of mixtures meeting the objective strength, selectivity, and ADME models in less emphasess, and with undeniably less information, than in any case conceivable. About Valence Discovery Valence is focused on opening the genuine capability of profound learning in drug plan by binding together top tier profound learning innovations with instinctive foundation to make these advances all the more extensively open to R&D associations, everything being equal. Valence's AI-empowered medication plan stage has been widely approved and is right now being utilized to distinguish and configuration drug applicants as a team with industry-driving accomplices. The organization is spearheading the utilization of few-shot learning in drug plan and is creating and conveying novel AI strategies for sub-atomic property expectation, generative science, and multiparameter advancement. Valence (once in the past InVivo AI) was established in 2018, is exhorted by profound learning pioneer, Dr. Yoshua Bengio, and is gladly settled in Montreal at Mila, the world's biggest profound learning research foundation, with an office in Cambridge, Mass. About Charles River Charles River gives fundamental items and administrations to help drug and biotechnology organizations, government offices and driving scholastic foundations all throughout the planet speed up their exploration and medication improvement endeavors. Our devoted workers are centered around giving customers precisely what they need to improve and assist the disclosure, beginning phase advancement and safe production of new treatments for the patients who need them.

Read More

AXON Neuroscience, a Clinical-stage Biotech Company to Launch World's First Crowdfunded Vaccine Against Covid-19

COVIDAX | September 19, 2020

AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 – ACvac1. With more than 20 years of experience developing an exceptionally safe and immunogenic peptide vaccine against dementia, in April 2020 Axon announced its plan to develop a novel peptide vaccine against COVID-19. Axon's scientists identified the weakest points of the SARS-CoV-2 virus and used them to design the vaccine. ACvac1 induced extensive antibody production in vaccinated mice, effectively blocking the live virus from replicating and confirming the soundness of Axon's approach. Axon plans to begin first-in-human trials as early as the fourth quarter of 2020. Based on these encouraging vaccine efficacy results, Axon has decided to open the project to individuals and small investors who will be able to invest directly from the project's website.

Read More

Arctic Vision Announces US$32MN in Series A to Expand Innovative Product Portfolio in Ophthalmology

Arctic Vision | July 15, 2020

Arctic Vision, a clinical-stage biotechnology company incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China in 2019, today announced its $32mn Series A financing led by Morningside Ventures, together with its existing investors. Arctic Vision focuses on the development and commercialization of innovative ophthalmology therapies in China and Asia. The three investment institutions are actively investing in leading life science companies in the world with long term commitment.Arctic Vision will use the proceeds to gear up the clinical trials for ARVN001. ARVN001 is a proprietary suspension of the Triamcinolone Acetonide formulated for Suprachoroidal Space (SCS) administration via proprietary SCS Microinjector™ (known as XIPERE™ in the US). The first pursued indication in China will be macular edema associated with uveitis (UME). This innovative therapy is developed by Clearside Biomedical, Inc. Arctic Vision has exclusive rights to develop and commercialize the product in Greater China and South Korea.Arctic Vision also plans to use the proceeds to expand its innovative product portfolio in ophthalmology, while building in-house R&D capabilities at the same time. The company's goal is to address unmet medical needs in the ophthalmology field, and to bring in cutting-edge drug delivery technologies and treatment options to the Asian market, especially China.

Read More